XML 24 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Revenue:      
Precision oncology testing $ 687,936 $ 514,249 $ 392,049
Development services and other 51,080 49,699 57,489
Total revenue 739,016 563,948 449,538
Costs and operating expenses:      
Cost of precision oncology testing 260,581 205,528 148,199
Cost of development services and other 29,218 21,524 8,126
Research and development expense 347,753 367,194 373,807
Sales and marketing expense 364,935 295,227 299,828
General and administrative expense 180,123 155,800 163,956
Other operating expense 0 83,400 0
Total costs and operating expenses 1,182,610 1,128,673 993,916
Loss from operations (443,594) (564,725) (544,378)
Interest income 53,691 35,365 6,069
Interest expense (2,581) (2,578) (2,577)
Other income (expense), net (42,605) 53,174 (12,778)
Fair value adjustments of noncontrolling interest liability 0 0 (99,785)
Loss before provision for income taxes (435,089) (478,764) (653,449)
Provision for income taxes 1,284 685 1,139
Net loss $ (436,373) $ (479,449) $ (654,588)
Net loss per share, basic (in usd per share) $ (3.56) $ (4.28) $ (6.41)
Net loss per share, diluted (in usd per share) $ (3.56) $ (4.28) $ (6.41)
Weighted-average shares used in computing net loss per share, basic (in shares) 122,745 111,988 102,178
Weighted-average shares used in computing net loss per share, diluted (in shares) 122,745 111,988 102,178